08:14 AM EDT, 03/11/2026 (MT Newswires) -- Crispr Therapeutics ( CRSP ) said Wednesday it has priced $550 million of convertible senior notes due 2031 in a private offering, with an option for initial purchasers to buy up to an additional $50 million.
The company said the offering, upsized from $350 million, is expected to close Monday.
Crispr said the proceeds will be used for general corporate purposes.